{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:11:52Z","timestamp":1794373912694,"version":"4.9.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7691","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1038\/nature25456","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T09:36:36Z","timestamp":1517391396000},"page":"249-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1624,"title":["High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"554","author":[{"given":"Akinori","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L.","family":"Villemagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Doecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Dor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Arahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"BFnature25456_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016)","journal-title":"Nature"},{"key":"BFnature25456_CR2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"R Sperling","year":"2014","unstructured":"Sperling, R., Mormino, E. & Johnson, K. The evolution of preclinical Alzheimer\u2019s disease: implications for prevention trials. Neuron 84, 608\u2013622 (2014)","journal-title":"Neuron"},{"key":"BFnature25456_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jalz.2013.01.013","volume":"10","author":"K Henriksen","year":"2014","unstructured":"Henriksen, K. et al. The future of blood-based biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. 10, 115\u2013131 (2014)","journal-title":"Alzheimers Dement."},{"key":"BFnature25456_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jalz.2016.09.014","volume":"13","author":"SE O\u2019Bryant","year":"2017","unstructured":"O\u2019Bryant, S. E. et al. Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement. 13, 45\u201358 (2017)","journal-title":"Alzheimers Dement."},{"key":"BFnature25456_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jalz.2012.12.006","volume":"10","author":"A Rembach","year":"2014","unstructured":"Rembach, A. et al. Changes in plasma amyloid \u03b2 in a longitudinal study of aging and Alzheimer\u2019s disease. Alzheimers Dement. 10, 53\u201361 (2014)","journal-title":"Alzheimers Dement."},{"key":"BFnature25456_CR6","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.jalz.2013.01.007","volume":"10","author":"S Swaminathan","year":"2014","unstructured":"Swaminathan, S. et al. Association of plasma and cortical amyloid beta is modulated by APOE \u03b54 status. Alzheimers Dement. 10, e9\u2013e18 (2014)","journal-title":"Alzheimers Dement."},{"key":"BFnature25456_CR7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jalz.2016.12.004","volume":"13","author":"H L\u00f6vheim","year":"2017","unstructured":"L\u00f6vheim, H. et al. Plasma concentrations of free amyloid \u03b2 cannot predict the development of Alzheimer\u2019s disease. Alzheimers Dement. 13, 778\u2013782 (2017)","journal-title":"Alzheimers Dement."},{"key":"BFnature25456_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2183\/pjab.90.353","volume":"90","author":"N Kaneko","year":"2014","unstructured":"Kaneko, N. et al. Novel plasma biomarker surrogating cerebral amyloid deposition. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 90, 353\u2013364 (2014)","journal-title":"Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci."},{"key":"BFnature25456_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod, V. et al. Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 13, 841\u2013849 (2017)","journal-title":"Alzheimers Dement."},{"key":"BFnature25456_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bfgp\/elm010","volume":"6","author":"V Gelfanova","year":"2007","unstructured":"Gelfanova, V. et al. Quantitative analysis of amyloid-\u03b2 peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Brief. Funct. Genomic. Proteomic. 6, 149\u2013158 (2007)","journal-title":"Brief. Funct. Genomic. Proteomic."},{"key":"BFnature25456_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2183\/pjab.90.104","volume":"90","author":"N Kaneko","year":"2014","unstructured":"Kaneko, N., Yamamoto, R., Sato, T. A. & Tanaka, K. Identification and quantification of amyloid b-related peptides in human plasma using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 90, 104\u2013117 (2014)","journal-title":"Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci."},{"key":"BFnature25456_CR12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1017\/S1041610209009405","volume":"21","author":"KA Ellis","year":"2009","unstructured":"Ellis, K. A. et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer\u2019s disease. Int. Psychogeriatr. 21, 672\u2013687 (2009)","journal-title":"Int. Psychogeriatr."},{"key":"BFnature25456_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe, R. et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann. Neurol. 68, 319\u2013329 (2010)","journal-title":"Ann. Neurol."},{"key":"BFnature25456_CR14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2967\/jnumed.109.069088","volume":"51","author":"DF Wong","year":"2010","unstructured":"Wong, D. F. et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F 18). J. Nucl. Med. 51, 913\u2013920 (2010)","journal-title":"J. Nucl. Med."},{"key":"BFnature25456_CR15","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1007\/s00259-014-2753-3","volume":"41","author":"SM Landau","year":"2014","unstructured":"Landau, S. M. et al. Amyloid PET imaging in Alzheimer\u2019s disease: a comparison of three radiotracers. Eur. J. Nucl. Med. Mol. Imaging 41, 1398\u20131407 (2014)","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"BFnature25456_CR16","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1212\/WNL.0000000000000431","volume":"82","author":"EC Mormino","year":"2014","unstructured":"Mormino, E. C. et al. Amyloid and APOE \u03b54 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82, 1760\u20131767 (2014)","journal-title":"Neurology"},{"key":"BFnature25456_CR17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.9734\/AIR\/2014\/11599","volume":"2","author":"VL Villemagne","year":"2014","unstructured":"Villemagne, V. L. et al. En attendant centiloid. Adv. Res. 2, 723\u2013729 (2014)","journal-title":"Adv. Res."},{"key":"BFnature25456_CR18","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/archneurol.2011.105","volume":"68","author":"AM Fagan","year":"2011","unstructured":"Fagan, A. M. et al. Comparison of analytical platforms for cerebrospinal fluid measures of \u03b2-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch. Neurol. 68, 1137\u20131144 (2011)","journal-title":"Arch. Neurol."},{"key":"BFnature25456_CR19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1001\/archneurol.2012.26","volume":"69","author":"DJ Irwin","year":"2012","unstructured":"Irwin, D. J. et al. Comparison of cerebrospinal fluid levels of tau and A\u03b2 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch. Neurol. 69, 1018\u20131025 (2012)","journal-title":"Arch. Neurol."},{"key":"BFnature25456_CR20","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","volume":"73","author":"WJ Jagust","year":"2009","unstructured":"Jagust, W. J. et al. Relationships between biomarkers in aging and dementia. Neurology 73, 1193\u20131199 (2009)","journal-title":"Neurology"},{"key":"BFnature25456_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3233\/JAD-150247","volume":"48","author":"QX Li","year":"2015","unstructured":"Li, Q. X. et al. Alzheimer\u2019s disease normative cerebrospinal fluid biomarkers validated in PET amyloid-\u03b2 characterized subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J. Alzheimers Dis. 48, 175\u2013187 (2015)","journal-title":"J. Alzheimers Dis."},{"key":"BFnature25456_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw, L. M. et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann. Neurol. 65, 403\u2013413 (2009)","journal-title":"Ann. Neurol."},{"key":"BFnature25456_CR23","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrneurol.2017.111","volume":"13","author":"J Wang","year":"2017","unstructured":"Wang, J., Gu, B. J., Masters, C. L. & Wang, Y. J. A systemic view of Alzheimer disease - insights from amyloid-\u03b2 metabolism beyond the brain. Nat. Rev. Neurol. 13, 612\u2013623 (2017)","journal-title":"Nat. Rev. Neurol."},{"key":"BFnature25456_CR24","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze, S. et al. Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci. Rep. 6, 26801 (2016)","journal-title":"Sci. Rep."},{"key":"BFnature25456_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3233\/JAD-131802","volume":"40","author":"A Rembach","year":"2014","unstructured":"Rembach, A. et al. Plasma amyloid-\u03b2 levels are significantly associated with a transition toward Alzheimer\u2019s disease as measured by cognitive decline and change in neocortical amyloid burden. J. Alzheimers Dis. 40, 95\u2013104 (2014)","journal-title":"J. Alzheimers Dis."},{"key":"BFnature25456_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1749-6632.1993.tb23043.x","volume":"695","author":"JT Jarrett","year":"1993","unstructured":"Jarrett, J. T., Berger, E. P. & Lansbury, P. T., Jr. The C-terminus of the \u03b2 protein is critical in amyloidogenesis. Ann. NY Acad. Sci. 695, 144\u2013148 (1993)","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnature25456_CR27","unstructured":"Rogers, M. B. Are CSF Assays Finally Ready for Prime Time? Alzforum\n                    https:\/\/www.alzforum.org\/news\/conference-coverage\/are-csf-assays-finally-ready-prime-time\n                    \n                   (2017)"},{"key":"BFnature25456_CR28","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaneurol.2016.3751","volume":"73","author":"M Boccardi","year":"2016","unstructured":"Boccardi, M. et al. Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: the incremental diagnostic value of amyloid PET with [18F]-florbetapir (INDIA-FBP) Study. JAMA Neurol. 73, 1417\u20131424 (2016)","journal-title":"JAMA Neurol."},{"key":"BFnature25456_CR29","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1001\/jamaneurol.2016.3792","volume":"73","author":"RJ Caselli","year":"2016","unstructured":"Caselli, R. J. & Woodruff, B. K. Clinical impact of amyloid positron emission tomography\u2014is it worth the cost? JAMA Neurol. 73, 1396\u20131398 (2016)","journal-title":"JAMA Neurol."},{"key":"BFnature25456_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jalz.2014.08.099","volume":"11","author":"SE O\u2019Bryant","year":"2015","unstructured":"O\u2019Bryant, S. E. et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer\u2019s disease research. Alzheimers Dement. 11, 549\u2013560 (2015)","journal-title":"Alzheimers Dement."},{"key":"BFnature25456_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 270\u2013279 (2011)","journal-title":"Alzheimers Dement."},{"key":"BFnature25456_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging\u2013Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011)","journal-title":"Alzheimers Dement."},{"key":"BFnature25456_CR33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","volume":"31","author":"CC Rowe","year":"2010","unstructured":"Rowe, C. C. et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 31, 1275\u20131283 (2010)","journal-title":"Neurobiol. Aging"},{"key":"BFnature25456_CR34","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1016\/j.neurobiolaging.2014.04.033","volume":"36","author":"P Bourgeat","year":"2015","unstructured":"Bourgeat, P. et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol. Aging 36, S159\u2013S166 (2015)","journal-title":"Neurobiol. Aging"},{"key":"BFnature25456_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark, C. M. et al. Use of florbetapir-PET for imaging \u03b2-amyloid pathology. J. Am. Med. Assoc. 305, 275\u2013283 (2011)","journal-title":"J. Am. Med. Assoc."},{"key":"BFnature25456_CR36","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.2967\/jnumed.112.115006","volume":"54","author":"R Lundqvist","year":"2013","unstructured":"Lundqvist, R. et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J. Nucl. Med. 54, 1472\u20131478 (2013)","journal-title":"J. Nucl. Med."},{"key":"BFnature25456_CR37","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3233\/JAD-2012-121471","volume":"33","author":"J Pannee","year":"2013","unstructured":"Pannee, J. et al. A selected reaction monitoring (SRM)-based method for absolute quantification of A\u03b238, A\u03b240, and A\u03b242 in cerebrospinal fluid of Alzheimer\u2019s disease patients and healthy controls. J. Alzheimers Dis. 33, 1021\u20131032 (2013)","journal-title":"J. Alzheimers Dis."},{"key":"BFnature25456_CR38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ana.24454","volume":"78","author":"BW Patterson","year":"2015","unstructured":"Patterson, B. W. et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann. Neurol. 78, 439\u2013453 (2015)","journal-title":"Ann. Neurol."},{"key":"BFnature25456_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/13506120902879848","volume":"16","author":"C Manzoni","year":"2009","unstructured":"Manzoni, C. et al. Overcoming synthetic A\u03b2 peptide aging: a new approach to an age-old problem. Amyloid 16, 71\u201380 (2009)","journal-title":"Amyloid"},{"key":"BFnature25456_CR40","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.1471-4159.2012.07707.x","volume":"121","author":"D Schlenzig","year":"2012","unstructured":"Schlenzig, D. et al. N-Terminal pyroglutamate formation of A\u03b238 and A\u03b240 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation. J. Neurochem. 121, 774\u2013784 (2012)","journal-title":"J. Neurochem."},{"key":"BFnature25456_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/alzrt236","volume":"6","author":"J Toombs","year":"2014","unstructured":"Toombs, J., Paterson, R. W., Schott, J. M. & Zetterberg, H. Amyloid-beta 42 adsorption following serial tube transfer. Alzheimers Res. Ther. 6, 5 (2014)","journal-title":"Alzheimers Res. Ther."},{"key":"BFnature25456_CR42","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1021\/pr500155z","volume":"13","author":"S Tanaka","year":"2014","unstructured":"Tanaka, S. et al. Mass++: A visualization and analysis tool for mass spectrometry. J. Proteome Res. 13, 3846\u20133853 (2014)","journal-title":"J. Proteome Res."},{"key":"BFnature25456_CR43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","volume":"9","author":"N Mattsson","year":"2013","unstructured":"Mattsson, N. et al. CSF biomarker variability in the Alzheimer\u2019s Association quality control program. Alzheimers Dement. 9, 251\u2013261 (2013)","journal-title":"Alzheimers Dement."},{"key":"BFnature25456_CR44","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/biomet\/52.3-4.591","volume":"52","author":"SS Shapiro","year":"1965","unstructured":"Shapiro, S. S. & Wilk, M. B. An analysis of variance test for normality (complete samples). Biometrika 52, 591\u2013611 (1965)","journal-title":"Biometrika"},{"key":"BFnature25456_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32\u201335 (1950)","journal-title":"Cancer"},{"key":"BFnature25456_CR46","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837\u2013845 (1988)","journal-title":"Biometrics"},{"key":"BFnature25456_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","volume":"27","author":"MJ Pencina","year":"2008","unstructured":"Pencina, M.J., D\u2019Agostino, R.B. Sr., D\u2019Agostino, R.B. Jr. & Vasan, R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 27, 157\u2013172 (2008)","journal-title":"Stat. Med."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature25456.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature25456","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nature25456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nature25456.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:11:37Z","timestamp":1684419097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature25456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":47,"journal-issue":{"issue":"7691","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["BFnature25456"],"URL":"https:\/\/doi.org\/10.1038\/nature25456","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"22 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.K., S.I. and K.T. are employees of Shimadzu. NCGG and Shimadzu have patents pending that are related to this study: PCT\/JP2016\/076706 and PCT\/JP2015\/064386. Shimadzu has patents pending: JP 2015-140899 and US 15\/209331. V.L.V. received grants from CSIRO and NHMRC during the study. J.D. received grants from CRC for Mental Health, during the study, and has patent TW8546\/AU pending.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}